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OBJECTIVES: To assess the budgetary impact of XELOX (com-
bination regimen of Xeloda plus oxaliplatine) as a treatment
option in colorectal cancer in Italy. METHODS: A matrix model
was developed to estimate the budgetary impact of XELOX from
the perspective of the health care purchaser in Italy in 2008. The
analysis was performed for patients with colorectal cancer receiv-
ing 5-FU, FOLFOX-4 (or FOLFOX-6 or FOLFOX-6 modiﬁed),
FOLFIRI, Xeloda (capecitabine), who are eligible for treatment
with XELOX. Data sources used include published literature,
ofﬁcial Italian price/tariff lists, and national population statistics.
The analysis covers adjuvant therapy for colon cancer and 1st
and 2nd line treatment in metastatic colorectal cancer (mCRC)
over a 5-year time horizon. The perspective of the analysis was
that of the NHS in Italy in 2008. RESULTS: The analysis shows
that the total treatment costs decrease when XELOX is intro-
duced as a treatment option in colorectal cancer. The introduc-
tion of XELOX leads to cost savings at the national level of €65
million over a period of 5 years, when the FOLFOX regimen
consists of FOLFOX-4. The use of XELOX leads to additional
costs of €154 million for XELOX, but these costs are offset by
cost savings for the other regimens and especially FOLFOX
(€171 million) and FOLFIRI (€26 million). For FOLFOX-6 and
FOLFOX-6 modiﬁed the cost savings are respectively €52 and of
€22 million. Sensitivity analyses conﬁrmed the robustness of the
outcome of the model. CONCLUSIONS: The use of XELOX
leads to a positive impact on the national drug budget in terms of
costs savings in patients with colorectal cancer.
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OBJECTIVES: To estimate the impact on the budget of the
Public Payer in Poland of the continuation of docetaxel reim-
bursement in the neoadjuvant therapy of locally advanced breast
cancer (LABC) and palliative therapy of metastatic breast cancer
(MBC) due to rising needs. METHODS: Analysis was performed
from the public payers’ perspective (National Health Fund) in
Poland. Two scenarios were compared: present and future. Doc-
etaxel is reimbursed in Poland for patients who fulﬁll special
requirements (limited reimbursement). In the “present scenario”
it was assumed that the number of patients is equal to the
number of patients treated in 2007 year. In the “future scenario”
it was assumed that the target population for docetaxel treatment
will increase in the following years 2008–2012 due to better
patient diagnosis and increase in disease incidence. for patients
who fulﬁll special requirements (limited reimbursement). In the
“present scenario” it was assumed that the number of patients is
equal to the number of patients treated in 2007 year. In the
“future scenario” it was assumed that the target population for
docetaxel treatment will increase in the following years 2008–
2012 due to better patient diagnosis and increase in disease
incidence. Two scenarios were compared: present and future.
Docetaxel is reimbursed in for patients who fulﬁll special require-
ments (limited reimbursement). In the “present scenario” it was
assumed that the number of patients is equal to the number of
patients treated in 2007 year. In the “future scenario” it was
assumed that the target population for docetaxel treatment will
increase in the following years 2008–2012 due to better patient
diagnosis and increase in disease incidence. RESULTS: Estimated
number of patients who will be treated (with restrictions) with
docetaxel will increase from 2278 in 2008 to 2550 in 2012.
Compared to 2007 total increase in number of patients will
amount from 135 to 407 patients annually. Assuming continua-
tion of docetaxel reimbursement in the treatment of LABC and
MBC in years 2008–2012, the incremental expenses of the Public
Payer to ﬁnance the treatment with docetaxel will amount 3,28
mln PLN in 2008 up to 11,23 mln PLN in 2012. Incremental
QALYs will amount from 66 to 233 in 2008 and 2012 respec-
tively. Incremental LYG will amount from 76 to 254 years in
2008 to 2012 respectively. CONCLUSIONS: Continuation of
docetaxel reimbursement in the treatment of LABC and MBC
will not considerably inﬂuence the expenses of the Public Payer in
Poland. Treatment with docetaxel improves survival and func-
tional outcomes compared with standard care. Discontinuation
of the therapeutic program reimbursement would cause signiﬁ-
cant decrease of the total incremental effect among patients with
locally advanced and metastatic breast cancer. . Treatment with
docetaxel improves survival and functional outcomes compared
with standard care. Discontinuation of the therapeutic program
reimbursement would cause signiﬁcant decrease of the total
incremental effect among patients with locally advanced and
metastatic breast cancer.
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OBJECTIVES: To demonstrate the pharmacoeconomic savings
provided by panitumumab (Vectibix®), a fully human anti-
EGFR monoclonal antibody (mAB) when compared with cetux-
imab (Erbitux®), a chimeric mAB, based on practical usage
considerations in metastatic colorectal cancer (mCRC) patients,
from the Italian Payers’ perspective. METHODS: The model
demonstrated the annual savings provided by panitumumab
versus cetuximab in a cohort of patients by grouping them into
three distinct areas; low-weight patient savings, administration
savings and safety savings. The products were compared based
on dosing, administration and safety data from the product
labels. Given the lower incidence of grade IV infusion reactions
expected with panitumumab compared with cetuximab, safety
savings were calculated by multiplying the comparative differ-
ence in frequency of infusion reactions by the Diagnosis-Related
Group (DRG) for an anaphylactic shock. Administration savings
compared the dosing schedules of panitumumab (biweekly) and
cetuximab (weekly). Therapy visit costs were based on national
tariffs (outpatient DRGs). For the average patient, with a weight
of 73 kg and a surface area of 1.7 m2, panitumumab and cetux-
imab are priced at parity. However, over a range of patients, the
average cost for panitumumab will be lower. The model used the
normal distribution and the mean and standard deviations for
weight and surface area, gained from an Italian retrospective
patient survey, to deﬁne the cohort and calculate average savings
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over different combinations of patient weight and surface area.
RESULTS: Savings of €3,404 per course per patient were shown;
potentially saving the Italian health care system €7.67 million per
year. This assumes that of the 2,252 third-line patients, 57%
receive panitumumab and 43% receive Active Supportive Care in
Year 1 based on the prevalence of the wild-type K-RAS mutation,
compared with 100% receiving cetuximab. CONCLUSIONS:
Results indicate that substantial savings are associated with pani-
tumumab therapy over cetuximab therapy at national and per-
patient levels.
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OBJECTIVES: This study evaluates the cost-effectiveness and
the budget impact of ixabepilone, a new microtubule stabilizer
for treatment of breast cancer, as part of the Formulary Man-
agement System at a major tertiary cancer center in the United
States. METHODS: A decision analytical model was developed
to estimate the incremental cost-effectiveness of ixabepilone for
breast cancer, in patients who failed treatment with anthracy-
cline and taxane. The model compared two strategies: combi-
nation therapy of ixabepilone with capecitabine compared to
capecitabine alone. The outcome of interest was progression
free life year (PFLY), based on published literature and clinical
use estimates. Direct institutional medical costs for a one-year
time period were utilized. One-way and two-way sensitivity
analyses on the probabilities of disease progression were con-
ducted. In addition, a budget impact analysis was also con-
ducted for adding ixabepilone in the Formulary. RESULTS:
Based on outcome estimates from literature and the application
of the institutional costs, the cost per PFLY saved for ixabepi-
lone for treatment of advanced breast cancer was $318,404.
One-way sensitivity analysis on the efﬁcacy probability (0–1.0)
of the combination therapy indicated that ixabepilone’s cost-
effectiveness ratios ranged from $205,000 to $1,190,000 per
PFLY saved. Two-way sensitivity analysis with a willingness-to-
pay threshold of $250,000 indicated that the majority of the
time monotherapy is the more cost-effective option. Only if
the probability of response to the combination is >30% and the
probability of response to the monotherapy is <33%, does the
combination therapy become more cost-effective. The budget
impact model showed that the institution will utilize about
$7.39 million worth of ixabepilone annually based on acquisi-
tion costs. CONCLUSIONS: Ixabepilone appears to be less
cost-effective than other neoplastic agents for treatment of
breast cancer. Future economic analyses will be conducted to
determine how closely the current economic model predicts
actual utilization and cost-effectiveness at the institution.
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OBJECTIVES: The purpose of this study was to analyse the
disease-related costs as well as the side effect hand-foot syndrome
(HFS) in oncologic patients receiving capecitabine. HFS is a dose
and therapy limiting toxicity which is classiﬁed into severity
grades 1 to 3. METHODS: Between April 2006 and August 2007
an observational study was conducted in Bonn, Germany on two
oncologic outpatient wards and three oncologic practices. Breast
and colorectal cancer patients starting oral chemotherapy with
capecitabine were included and followed for six months. They
rated their HFS at the end of each capecitabine cycle. The HFS
grades were transformed into utility weights obtained from an
earlier study in our group. From the perspective of the German
statutory health insurance the direct disease-related costs (out-
patient costs for pharmacotherapy, oncologist visits, diagnostics
and inpatient costs) were assessed in a microcosting approach
and referred to 2008. RESULTS: Thirty patients (16 breast, 14
colorectal cancer) were included. Their mean HFS severity grade
was 1.1 (SD 0.7, median 1.0, range 0 to 2.75) corresponding to
a mean utility weight of 0.88 (SD 0.14, median 0.92, range 1.00
to 0.44). Seven patients showed a HFS grade 3 (utility weight:
0.34) at least in one capecitabine cycle. On average €18,305
(80.4% outpatient, 19.6% inpatient) were calculated per breast
cancer patient and €25,863 (71.2% outpatient, 28.8% inpatient)
per colorectal cancer patient. Concerning the outpatient treat-
ment, costs for pharmacotherapy represented the highest matter
of expense (96.0% breast, 95.0% colorectal cancer). CONCLU-
SIONS: In most patients HFS occurred in moderate severity.
Nevertheless, 7 patients experienced HFS grade 3 affecting
quality of life. Strategies to prevent this toxicity need to be
developed. Especially costs for pharmacotherapy represent a
cost-driving factor in this patient group indicating a need for
strategies to optimize cost structure while containing or improv-
ing quality of treatment.
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OBJECTIVES: Panitumumab is the ﬁrst fully human anti-EGFR
monoclonal antibody to be approved as monotherapy for
patients with wild type (wt) KRAS mCRC after failure of
ﬂuoropyrimidine-, oxaliplatin-, and irinotecan-containing che-
motherapy regimens. This novel treatment approach is the begin-
ning of a new era of personalised treatment whereby KRAS
status is evaluated and only patients who are likely to respond
(wt KRAS) receive treatment. The objective of this study was to
evaluate the overall budget impact (BI) of the use of panitu-
mumab versus testing KRAS and treating patients with wt KRAS
in Greece. METHODS: To consider overall costs associated with
panitumumab treatment versus testing KRAS status and treating
only wt KRAS patients with panitumumab, a decision analytic
model was developed to evaluate BI. Primary drug costs, con-
comitant medications, infusion costs, radiation therapy, clinic
visits, and hospitalisations were included in treatment costs. An
expert panel was employed to map mCRC patient ﬂow as a local
cancer registry was not available. In this analysis, cost calcula-
tions for the public and private sectors were conducted sepa-
rately. RESULTS: Out of 470 potentially eligible patients for
panitumumab monotherapy, the decision analytic model targets
268 (57%) patients with wt KRAS, according to indication.
Potential total cost of receiving panitumumab without taking
KRAS status into consideration was €8.4 million in the public
sector, while total cost including KRAS testing to all patients but
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